Krebsforschung Schweiz, Bern, Switzerland Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2015
NCT02088645
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Krebsforschung Schweiz, Bern, Switzerland

Active Ingredients

Drugs in Phase 1 Trials (2)

177lu-pp-f11n (2 trials)

sacubitril (Entresto) (1 trial)

Drugs in Other Trials (1)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Thyroid Diseases (Phase 1)

Thyroid Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3